Kazia Therapeutics Ltd. (KZIA) intrinsic value & 10-year financials
Kazia Therapeutics Ltd. (KZIA) has a Graham intrinsic value of AUD 1.18 per share. Over the last 10 fiscal years revenue shrank 22.3% a year to AUD 42.0K, with an average return on invested capital of 171.9%.
- Graham intrinsic value
- AUD 1.18
- Revenue (FY2025)
- AUD 42.0K
- Revenue growth (10-yr CAGR)
- -22.3%
- ROIC (10-yr avg)
- 171.9%
- Free cash flow (FY2025)
- —
KZIA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | AUD 42.0K | -AUD 20.7M | -AUD 0.04 | — | — | 177.8% |
| FY2024 | AUD 2.3M | -AUD 26.8M | -AUD 0.10 | — | — | 2199.2% |
| FY2023 | AUD 0 | -AUD 20.5M | -AUD 0.11 | — | — | -188.4% |
| FY2022 | AUD 0 | -AUD 24.6M | -AUD 0.19 | — | — | -187.9% |
| FY2021 | AUD 15.2M | -AUD 8.4M | -AUD 7.16 | — | — | -32.4% |
| FY2020 | — | -AUD 12.5M | -AUD 17.07 | — | — | -88.0% |
| FY2019 | — | -AUD 10.3M | -AUD 17.86 | — | — | -61.4% |
| FY2018 | AUD 119.0K | -AUD 6.0M | -AUD 12.48 | — | — | -27.1% |
| FY2017 | AUD 249.0K | -AUD 10.7M | -AUD 2.28 | -AUD 11.4M | — | -36.3% |
| FY2016 | AUD 406.0K | -AUD 12.2M | -AUD 2.82 | -AUD 12.5M | — | -36.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in AUD.
Executive summary
KAZIA THERAPEUTICS LTD is facing top-line stagnation, with revenue contracting over the decade.
KAZIA THERAPEUTICS LTD has historically struggled to out-earn its cost of capital, averaging just 5.0% ROIC.
KAZIA THERAPEUTICS LTD capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, KAZIA THERAPEUTICS LTD is modeled at -22.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.18 per share.